The US Government has procured another 200 million doses of the Pfizer–BioNTech Covid-19 vaccine, taking the total doses to be supplied to the country to 500 million. The latest doses will be supplied between October this year and April next year. This order is separate from the 500 million doses that the companies agreed to provide to the US government for donation to other countries.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Moderna’s Covid-19 vaccine, Spikevax, for use in adolescents aged 12 to 17 years. This recommendation will be considered by the European Commission for its approval. The vaccine is already authorised in more than 50 countries for emergency use in adults.
A new study has found that a single dose of AstraZeneca’s Covid-19 vaccine, Vaxzevria, showed 82% effectiveness against hospitalisation or death caused by the Beta/Gamma SARS-CoV-2 variants. In addition, the vaccine led to an 87% and 90% decrease in hospitalisations or deaths against the Delta and Alpha variants, respectively. The study was conducted by the Canadian Immunization Research Network and supported by the Public Health Agency of Canada and the Canadian Institutes of Health Research.